抗体

磷酸化CDKN1B多克隆抗体

MBS128516

0.05毫升

235美元

多克隆

兔

未共轭

人类, 小鼠, 大鼠

免疫印迹, 免疫组化

抗体

磷酸化CDKN1B多克隆抗体

[CDKN1B-T187]

[CDKN1B; CDKN4; KIP1; MEN1B; MEN4; P27KIP1; Cyclin-dependent kinase inhibitor 1B]

[Cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor 1B; cyclin-dependent kinase inhibitor 1B; cyclin-dependent kinase inhibitor 1B (p27, Kip1); Cyclin-dependent kinase inhibitor p27; p27Kip1]

[CDKN1B]

[CDKN1B;CDKN1B;KIP1;MEN4;CDKN4;MEN1B;P27KIP1;KIP1]

CDN1B_HUMAN

多克隆

IgG

兔

人类, 小鼠, 大鼠

198

亲和纯化

PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Store at -20 degree C. Avoid freeze / thaw cycles.

免疫印迹(免疫印迹), 免疫组化(免疫组化)

WB: 1:500 - 1:1000。 IHC: 1:50 - 1:100

免疫印迹(免疫印迹)

免疫组化(免疫组化)

Immunogen: A phospho specific peptide corresponding to residues surrounding T187 of human p27 KIP 1.

磷酸化

This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4).

1168871

P46527.1

P46527

Calculated: 22kDa. Observed: 26kDa

AKT Phosphorylates Targets In The Cytosol Pathway (106475); Adaptive Immune System Pathway (366160); AhR Pathway (755436); C-MYB Transcription Factor Network Pathway (138073); Cell Cycle Pathway (530733); Cell Cycle Checkpoints Pathway (105739); Cell Cycle, Mitotic Pathway (105765); Cell Cycle Pathway (198811); Cell Cycle Pathway (83054); Cell Cycle Pathway (463)

This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4). [provided by RefSeq, Apr 2014]

p27Kip1: a cell-cycle regulatory protein that Interacts with cyclin-CDK2 and -CDK4, inhibiting cell cycle progression at G1. May mediate TGF beta-induced g1 arrest. Its degradation is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Protein type: Protein kinase, regulatory subunit; Cell cycle regulation; Oncoprotein; Inhibitor. Chromosomal Location of Human Ortholog: 12p13.1-p12. Cellular Component: nucleoplasm; cytoplasm; nucleus; cytosol; endosome. Molecular Function: cyclin-dependent protein kinase inhibitor activity; protein binding; chaperone binding; protein complex binding; caspase activator activity; Hsp70 protein binding; protein phosphatase binding; transforming growth factor beta receptor, cytoplasmic mediator activity. Biological Process: negative regulation of kinase activity; response to peptide hormone stimulus; nerve growth factor receptor signaling pathway; positive regulation of microtubule polymerization; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; response to estradiol stimulus; negative regulation of cell proliferation; sensory perception of sound; positive regulation of cell proliferation; response to glucose stimulus; negative regulation of mitotic cell cycle; cell cycle arrest; inner ear development; potassium ion transport; epidermal growth factor receptor signaling pathway; caspase activation; response to drug; phosphoinositide-mediated signaling; fibroblast growth factor receptor signaling pathway; negative regulation of cyclin-dependent protein kinase activity; negative regulation of cell motility; response to amino acid stimulus; response to cadmium ion; response to hypoxia; positive regulation of protein catabolic process; autophagic cell death; innate immune response; negative regulation of phosphorylation; negative regulation of cell growth; regulation of cyclin-dependent protein kinase activity; mitotic cell cycle; negative regulation of transcription, DNA-dependent; negative regulation of apoptosis; G1/S transition of mitotic cell cycle. Disease: Multiple Endocrine Neoplasia, Type Iv

0.05毫升

235美元

0.1毫升

350

0.2毫升

525